Construction of Dmd Gene Mutant Mice and Phenotype Verification in Muscle and Immune Systems

doi:10.12300/j.issn.1674-5817.2023.089

Abstract

Abstract:

Objective The aim is to utilize CRISPR/Cas9 gene editing technology to construct Dmd gene mutant mice with a point mutation in exon 23 of the Dmd gene. Subsequently, the phenotypic changes of the mice in muscles and immune systems are analyzed and verified, providing an evaluation model for Duchenne muscular dystrophy and other related diseases. Methods Based on the sequence characteristics of exon 23 of the Dmd gene, small guide RNA (sgRNA) was designed and synthesized. Cas9 mRNA, sgRNA fragments, and oligo donor DNA were microinjected into fertilized eggs of C57BL/6J mice. After transferring the fertilized eggs to surrogate mice, F0 generation mice were born. After mating with F0 generation mice, offspring mice were obtained, and Dmd gene positive mutant (Dmd^Mu/+) mice were obtained after genotype identification. Male hemizygous Dmd^Mu/+(Dmd^Mu/Y) mice were selected for phenotype validation. The body weight of live 3- and 9-month-old mice were recorded. Muscle tension was evaluated through the grid test. Hearts and semitendinosus muscles were collected, and the histopathological changes were observed using HE staining. Further, the expression of Dmd protein in muscle tissue of 9-month-old mice was analyzed by Western blotting. An acute inflammation model was established in Dmd^Mu/Y mice using lipopolysaccharide induction. Peripheral blood from the submandibular vein was collected, and the changes in the proportion of neutrophils and monocytes were detected by flow cytometry. Results The results of genome sequencing and Western blotting confirmed the successful construction of Dmd gene point mutant mice (Dmd^Mu/+ mice). Dmd protein expression was not detected in skeletal muscle and myocardium of Dmd^Mu/+ mice, and it was significantly reduced compared to wild-type C57BL/6J mice (P<0.05). Compared with wild-type mice of the same background, Dmd^Mu/Y mice at 3 and 9 months of age showed significant weight loss (P<0.01) and decreased muscle tension (P<0.05). 9-month-old Dmd^Mu/Y mice exhibited significant pathological changes in skeletal muscle and myocardium, including widening of intermuscular space. Under normal condition, compared with wild-type mice, the proportion of neutrophils and monocytes in the peripheral blood of 3-month-old Dmd^Mu/Y mice was significantly lower than that of wild-type mice (P<0.01). After lipopolysaccharide stimulation, the proportion of neutrophils in peripheral blood of 3-month-old Dmd^Mu/Y mice remained significantly lower compared to that of wild-type mice (P<0.01). The proportion of neutrophils in peripheral blood of 9-month-old Dmd^Mu/Y mice significantly decreased after lipopolysaccharide induction (P<0.01), with a trend of change observed in monocytes between groups. Conclusion The successful construction of the Dmd gene mutant mouse model has confirmed the vital function of Dmd gene in maintaining normal muscle tissue morphology and muscle tone. It preliminarily indicated that Dmd gene deletion could significantly reduce the proportion of neutrophils in peripheral blood, offering a new perspective for the study of immune system alterations in Duchenne muscular dystrophy patients.

Key words: Dmd gene, CRISPR/Cas9, Duchenne muscular dystrophy, C57BL/6J mice

CLC Number:

Q95-33

Min LIANG,Yang GUO,Jinjin WANG,et al. Construction of Dmd Gene Mutant Mice and Phenotype Verification in Muscle and Immune Systems[J]. Laboratory Animal and Comparative Medicine, 2024, 44(1): 42-51. DOI: 10.12300/j.issn.1674-5817.2023.089.

Figures/Tables 5

Figure 1 Construction strategy of Dmd gene point mutation mice

Table 1 sgRNA and oligo donor DNA as well as PCR primer sequence information

序列名称

Sequence name

序列（5'→3'）

Sequence (5'→3')

小向导RNA

sgRNA

TCTTTGAAAGAGCAACAAAATGG

寡核苷酸供体DNA

Oligo donor DNA

GCTCTGCAAAGTTCTTTGAAAGAGCAATAAAATGGCTTCAACTATCTGAGTGACACTGTGAAGGAGATGGCCAAGAAAGCACCTTCAGAAATATGCCAGAAATATCTGTC

引物I

Primer I

ATGCTTGATATTGAGTAGTTA

引物 II

Primer II

AATAGATTTGGCTTTTGAT

测序引物

Sequencing primer

ATGCTTGATATTGAGTAGTTA

Figure2 Genotype results of Dmd point mutant miceNote：A， identification strategy diagram； B， PCR electrophoresis maps of DmdMu/+ mice； C-D， DNA sequencing results. DmdMu/+， heterozygous point mutant mice； WT， wild-type mice； M， DNA marker.

Figure 3 Phenotypic validation of DmdMu/Y miceNote：A-B, The expression levels of Dmd protein in semitendinosus (ST) and heart of DmdMu/Y mice were detected by Western blotting [wild-type C57BL/6J mice (WT) were used as the control group; GAPDH was internal control protein; n=3, *P<0.05, **P<0.01]; C, the body weight of 3-month and 9-month old DmdMu/Y mice [wild-type C57BL/6J mice (WT) were used as the control group; n=9, **P<0.01]; D, HE staining results of muscle tissue pathologic changes in 3-month and 9-month old DmdMu/Y mice [wild-type C57BL/6J mice (WT) were used as the control group; the gap between skeletal (ST) and myocardial (Heart) muscles of 9-month old DmdMu/Y mice became wider and the size of muscles varied; Infiltrating inflammatory cells were observed (sigh by arrow);n=3，bar=100 μm]. E, Schematic diagram of grid test; F, The statistical chart of the grid test [3-month old, DmdMu/Y mice n=6, WT mice n=5; 9-month old, DmdMu/Y mice n=8, WT mice n=5, *P<0.05, **P<0.01].

Figure 4 The proportion of neutrophils and monocytes in the blood of DmdMu/Y mice of LPS-induced acute inflammation model detected by flow cytometryNote： A-B, Changes in neutrophils ratio (A) and monocyte ratio (B) in 3-month old DmdMu/Y mice after injection of lipopolysaccharide (LPS) for 0 and 72 hours; C-D, Changes in neutrophils ratio (C) and monocyte ratio (D) in 9-month old DmdMu/Y mice after injection of LPS for 0 and 72 hours. The wild-type C57BL/6J mice (WT) were used as the control group; n=5, *P<0.05, **P<0.01.

References 29

1	NALLAMILLI B R R, CHAUBEY A, VALENCIA C A, et al. A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing[J]. Hum Mutat, 2021, 42(5):626-638. DOI: 10.1002/humu.24191 .
2	FORTUNATO F, FARNÈ M, FERLINI A. The DMD gene and therapeutic approaches to restore dystrophin[J]. Neuromuscul Disord, 2021, 31(10):1013-1020. DOI: 10.1016/j.nmd.2021.08.004 .
3	WANG L A, XU M, LI H A, et al. Genotypes and phenotypes of DMD small mutations in Chinese patients with dystrophinopathies[J]. Front Genet, 2019, 10:114. DOI: 10.3389/fgene.2019.00114 .
4	BRANDSEMA J F, DARRAS B T. Dystrophinopathies[J]. Semin Neurol, 2015, 35(4):369-384. DOI: 10.1055/s-0035-1558982 .
5	LINDSAY A, RUSSELL A P. The unconditioned fear response in dystrophin-deficient mice is associated with adrenal and vascular function[J]. Sci Rep, 2023, 13(1):5513. DOI: 10.1038/s41598-023-32163-w .
6	李少英, 孙筱放, 黎青, 等. 中国人群中抗肌萎缩蛋白基因突变类型和分布特点及其与临床症状的相关性[J]. 遗传, 2011, 33(3):251-254. DOI: 10.3724/SP.J.1005.2011.00251 .
	LI S Y, SUN X F, LI Q, et al. Association of mutation types and distribution characteristics of dystrophin gene with clinical symptoms in Chinese population[J]. Hereditas, 2011, 33(3):251-254. DOI: 10.3724/SP.J.1005.2011.00251 .
7	BHATTARAI S, LI Q A, DING J, et al. TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy[J]. Nat Commun, 2022, 13:879. DOI: 10.1038/s41467-022-28531-1 .
8	PETROF B J, PODOLSKY T, BHATTARAI S, et al. Trained immunity as a potential target for therapeutic immunomodulation in Duchenne muscular dystrophy[J]. Front Immunol, 2023, 14:1183066. DOI: 10.3389/fimmu.2023. 1183066 .
9	TULANGEKAR A, SZTAL T E. Inflammation in Duchenne muscular dystrophy-exploring the role of neutrophils in muscle damage and regeneration[J]. Biomedicines, 2021, 9(10):1366. DOI: 10.3390/biomedicines9101366 .
10	TRIPODI L, VILLA C, MOLINARO D, et al. The immune system in Duchenne muscular dystrophy pathogenesis[J]. Biomedicines, 2021, 9(10):1447. DOI: 10.3390/biomedicines 9101447 .
11	KURIBARA H, HIGUCHI Y, TADOKORO S. Effects of central depressants on rota-rod and traction performances in mice[J]. Jpn J Pharmacol, 1977, 27(1):117-126. DOI: 10.1254/jjp.27.117 .
12	姚庆和, 张华, 高国栋. 帕金森病小鼠模型行为学检测方法的比较研究[J]. 中国实验动物学报, 2006, 14(4): 264-270. DOI: 10.3969/j.issn.1005-4847.2006.04.006 .
	YAO Q H, ZHANG H, GAO G D. Comparison of behavioral tests in MPTP-induced Parkinson's disease in mice[J]. Acta Lab Animalis Sci Sin, 2006, 14(4): 264-270. DOI: 10.3969/j.issn.1005-4847.2006.04.006 .
13	MCGREEVY J W, HAKIM C H, MCINTOSH M A, et al. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy[J]. Dis Model Mech, 2015, 8(3):195-213. DOI: 10.1242/dmm.018424 .
14	GIBBS E M, HORSTICK E J, DOWLING J J. Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies[J]. FEBS J, 2013, 280(17):4187-4197. DOI: 10.1111/febs.12412 .
15	SICINSKI P, GENG Y, RYDER-COOK A S, et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation[J]. Science, 1989, 244(4912):1578-1580. DOI: 10.1126/science.2662404 .
16	BARTHÉLÉMY I, PINTO-MARIZ F, YADA E, et al. Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy[J]. Dis Model Mech, 2014, 7(11):1253-1261. DOI: 10.1242/dmm.016014 .
17	STIRM M, FONTEYNE L M, SHASHIKADZE B, et al. Pig models for Duchenne muscular dystrophy - from disease mechanisms to validation of new diagnostic and therapeutic concepts[J]. Neuromuscul Disord, 2022, 32(7):543-556. DOI: 10.1016/j.nmd.2022.04.005 .
18	LI J, WANG K Y, ZHANG Y C, et al. Therapeutic exon skipping through a CRISPR-guided cytidine deaminase rescues dystrophic cardiomyopathy in vivo [J]. Circulation, 2021, 144(22):1760-1776. DOI: 10.1161/CIRCULATIONAHA.121.054628 .
19	ZHANG Y, LI H, NISHIYAMA T, et al. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing[J]. Mol Ther Nucleic Acids, 2022, 29:525-537. DOI: 10.1016/j.omtn. 2022.07.024 .
20	WILLMANN R, POSSEKEL S, DUBACH-POWELL J, et al. Mammalian animal models for Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2009, 19(4):241-249. DOI: 10.1016/j.nmd.2008.11.015 .
21	董奇超, 陈慧敏. Duchenne型肌营养不良基因治疗研究进展[J]. 中国当代儿科杂志, 2018, 20(8): 691-697. DOI: 10.7499/j.issn.1008-8830.2018.08.017 .
	DONG Q C, CHEN H M. A review of gene therapy for Duchenne muscular dystrophy[J]. Chin J Contemp Pediatr, 2018, 20(8): 691-697. DOI: 10.7499/j.issn.1008-8830.2018.08.017 .
22	BULFIELD G, SILLER W G, WIGHT P A, et al. X chromosome-linked muscular dystrophy (mdx) in the mouse[J]. Proc Natl Acad Sci USA, 1984, 81(4):1189-1192. DOI: 10.1073/pnas. 81. 4.1189 .
23	GRIFFIN J L, WILLIAMS H J, SANG E, et al. Metabolic profiling of genetic disorders: a multitissue 1H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue[J]. Anal Biochem, 2001, 293(1):16-21. DOI: 10.1006/abio.2001.5096 .
24	MORRONI J, SCHIRONE L, VECCHIO D, et al. Accelerating the Mdx heart histo-pathology through physical exercise[J]. Life, 2021, 11(7):706. DOI: 10.3390/life11070706 .
25	RAZZOLI M, LINDSAY A, LAW M L, et al. Social stress is lethal in the mdx model of Duchenne muscular dystrophy[J]. EBioMedicine, 2020, 55:102700. DOI: 10.1016/j.ebiom. 2020. 102700 .
26	CHANG L L, NIU F N, CHEN J, et al. Ghrelin improves muscle function in dystrophin-deficient mdx mice by inhibiting NLRP3 inflammasome activation[J]. Life Sci, 2019, 232:116654. DOI: 10.1016/j.lfs.2019.116654 .
27	李想, 崔迪, 邱守涛. 白细胞介素-6在骨骼肌质量调节中的作用[J]. 中国生物化学与分子生物学报, 2023, 39(6):778-788. DOI: 10.13865/j.cnki.cjbmb.2022.09.1245 .
	LI X, CUI D, QIU S T. Interleukin-6 in skeletal muscle mass regulation[J]. Chin J Biochem Mol Biol, 2023, 39(6):778-788. DOI: 10.13865/j.cnki.cjbmb.2022.09.1245 .
28	JACKAMAN C, TOMAY F, DUONG L, et al. Aging and cancer: the role of macrophages and neutrophils[J]. Ageing Res Rev, 2017, 36:105-116. DOI: 10.1016/j.arr.2017.03.008 .
29	王颖. 脂多糖信号通路中的蛋白质修饰[J]. 中国生物化学与分子生物学报, 2008, 24(6):505-511. DOI: 10.13865/j.cnki.cjbmb.2008.06.013 .
	WANG Y. Post-translational modifications in regulation of lipopolysaccharide-activated signal transduction pathway[J]. Chin J Biochem Mol Biol, 2008, 24(6):505-511. DOI: 10.13865/j.cnki.cjbmb.2008.06.013 .

[1]	LIU Siyu, LAI Yuezhao, GUO Wenting, CHEN Xuejin. Advances in Nucleic Acid Drugs and Gene Therapies based on Animal Models of Duchenne Muscular Dystrophy [J]. Laboratory Animal and Comparative Medicine, 2024, 44(6): 613-625.
[2]	Yisu ZHANG, Xinru LIU, Ruojie WU, Rui LIU, Hong OUYANG, Xiaohong LI. Establishment and Evaluation of Mouse Model of Pregnancy Pain-depression Comorbidity Induced by Chronic Unpredictable Stress, Complete Freund's Adjuvant and Formalin [J]. Laboratory Animal and Comparative Medicine, 2024, 44(3): 259-269.
[3]	Han LI, Xiaorui ZHANG, Chengfang ZHANG. Mechanism of Intermittent Fasting in Improving Olanzapine-induced Metabolic Disorders in Mice [J]. Laboratory Animal and Comparative Medicine, 2023, 43(1): 3-10.
[4]	LAI Suomei, DING Yifu, LI Jinsong. A New Strategy for Constructing Mouse Models of Complex Diseases: Semi-cloning Technology Based on Sperm-like Haploid Embryonic Stem Cells [J]. Laboratory Animal and Comparative Medicine, 2021, 41(5): 369-383.
[5]	LI Zifa, ZHANG Hao, REN Meng, XU Kaiyong, HU Minghui, ZHOU Miaomiao, WANG Kezhou. Protective Effect of Quercetin on Lipid Metabolism Disorder in Mice Livers Caused by Cadmium [J]. Laboratory Animal and Comparative Medicine, 2021, 41(4): 305-312.
[6]	HONG Shenghui, ZHANG Xuliang, WANG Qianqian, LIU Ping, LIU Diwen. Construction of Inhibin Gene Knockout Mice and Preliminary Analysis of the Phenotype [J]. Laboratory Animal and Comparative Medicine, 2020, 40(4): 306-.
[7]	LEI Shan, LIU Qiang, HUANG Wei-jin, WANG You-chun. Influence of Strain, Gender and Hair Coat of Mice on Establishing Bioluminescent Imaging Pseudovirus Mouse Model [J]. Laboratory Animal and Comparative Medicine, 2019, 39(6): 423-428.
[8]	GAO Meng-qiao, AI Dong-xu, LI Yu, SUN Fei, WANG Jin, FAN Jun-wen, YUAN Zheng, LIU Yuan, SUN Zhao-zeng. The Construction of Ring Finger Protein 126 Gene Knockout Mouse by Using CRISPR/Cas9 Technique [J]. Laboratory Animal and Comparative Medicine, 2019, 39(1): 21-25.
[9]	ZHANG Qi, WANG Jian-fei. Progress and Perspective for Xenotransplantation [J]. Laboratory Animal and Comparative Medicine, 2018, 38(6): 407-411.
[10]	AI Dong-xu, ZHONG De-gang, SUN Fei, Li Yu, LI Chong, QIN Tong-tong, GAO Meng-qiao, DONG Shi-shi, SUN Zhao-zeng, LI Lian-rui. Construction of Lyst Gene Defective C57BL/6 Mice by CRISPR/Cas9 Technology [J]. Laboratory Animal and Comparative Medicine, 2018, 38(3): 202-206.
[11]	YANG Hua, ZHAO Ya-Juan, OU Qiang. Establishment of Nonalcoholic Fatty Liver Fibrosis Model and Expression of Inflammatory Factors in Mice [J]. Laboratory Animal and Comparative Medicine, 2017, 37(1): 20-24.
[12]	XIAO Nan1，ZHAO Wei2, BA Cai-feng2, SU Rong-jian1, SU Yu-hong1，3. Study on Gene Mutation and Muscles Subtypes’Expression in DMD Model Mice [J]. Laboratory Animal and Comparative Medicine, 2008, 28(6): 356-360.